Transcript Martel_EMCDDA

EMCDDA technical cooperation with
Western Balkan countries
P2P studtours, Brussels, 17 May 2011
General introduction
EMCDDA cooperation with non EU countries
EMCDDA: The EU drugs agency
• Who we are
• What we do
• Why we do it
• For whom?
Who we are
• A decentralised EU agency
• Formally established in 1993
• Based in Lisbon, Portugal
(operating since 1995)
• The hub of drug-related information
in the EU
What we do
• Provide the Community and EU Member States with:
‘factual, objective, reliable and comparable information at European level
concerning drugs and drug addiction and their consequences’
• New mission (2007) gives agency a broader role:
• collect, register, analyse information on ‘emerging trends in polydrug
use’, including combined use of licit and illicit psychoactive substances
• provide information on best practice in Member States and facilitate
exchange of such practice between them
Why we do it
• The EMCDDA works on the premise that sound information
is the key to effective drug strategies and policies.
Although the Centre cannot propose any kind of policy
model, it is now making a clear impact on decision-making
through its analyses, instruments and standards.
• The importance of evidence-based information on drugs to
inform policy-making is increasingly recognised.
Why we do it
• To generate a comparable, high-quality European
dataset and evidence base
• To understand what responses work
• To provide early-warning on new threats and
developments
• To support the evaluation of the EU drugs action plan
For whom?
• Policy-makers and their advisors
• Scientists and researchers
• Practitioners and drug professionals
• Media and general public
EMCDDA: Main tasks
• Collecting and analysing existing data
• Improving data-comparison methods
• Disseminating data
• Cooperating with European and international
bodies/organisations and with non-EU countries
Collecting and analysing existing data
Areas:
• Epidemiology — drug situation, monitoring new trends,
five key indicators
• Interventions — health, social and criminal justice responses
• Legislation — national and Community strategies and policies
• Policy — political and institutional framework, coordination
Collecting and analysing existing data
Methods:
• Reitox national focal points
(NFPs), national experts
• Annual reporting to EMCDDA
(national reports, standard
tables, questionnaires)
• Expert groups for developing
indicators (nominated by
NFPs)
• Ad hoc working groups
Improving data-comparison methods
• Improving the comparability of drug information across
Europe is at the heart of the Centre’s work
• EMCDDA methods, tools and guidelines help find a
‘common language’ to describe Europe’s drug situation
• Implementation of five epidemiological indicators in MS:
•
•
•
•
•
Drug use in the general population
Problem drug use
Drug-related deaths and mortality among drug users
Demand for treatment
Drug-related infectious diseases
Improving data-comparison methods
Areas under development:
•
•
•
•
•
•
crime (data on arrests, drug-related crime)
drug markets and availability (price, purity, seizures)
social exclusion
youth and vulnerability
new trends
best practice
Disseminating data
EMCDDA tailors products to specific user needs
It aims to speak to:
•
•
•
•
policy
science
practice
European citizen
EMCDDA publications
•
•
•
•
•
•
Annual report
General report of activities
Drugnet Europe (newsletter)
Drugs in focus (policy briefings)
EMCDDA Insights (hot topics)
EMCDDA Monographs
(scientific research)
• Manuals (evaluation)
• Risk assessments (new drugs)
• Thematic papers, technical data
sheets
Annual report — flagship product
• Annual report on the state of the
drugs problem in Europe
• Overview of the European drug
phenomenon in almost 30
countries
• Data and analyses: across
Europe and by country
• Latest trends and responses
Background documents
EMCDDA recast Regulation
‘transferring, at the request of the Commission
and with the approval of the MB referred to in
Article 9, its know-how to certain third
countries such as candidate countries or the
countries of the Western Balkans and assist in
the creation and strengthening of structural
links with the network referred to in article 5
and the setting up and consolidation of the
national focal points referred to in that article’.
Different forms of cooperation are possible
•
•
•
•
Simple exchange of information, data and /or
methodologies
Provision of ad hoc advice on the setting up or
running of drug observatories, drug information
systems etc.
Capacity-building through training and technical
assistance (light or intensive according to the status
of the country)
Full participation in the work of the EMCDDA by a
third country (a mid-term or long-term perspective,
depending on the status of the country where the EC
has negotiated an agreement
Candidate and potential candidate
countries
• In the framework of the enlargement and the
ultimate goal to become a member state
• Objective of the technical cooperation with
EMCDDA is to prepare the beneficiaries for
their participation within the EMCDDA
•
•
•
Candidate countries: Croatia, the former Yugoslav Republic of Macedonia,
Montenegro and Turkey.
Potential candidates: Albania, Bosnia and Herzegovina, Serbia as well as
Kosovo under UN Security Council Resolution 1244/99.
Iceland
20
Achievements under PHARE, CARDS and
IPA1
• NR in Croatia and in Turkey
• Participation in EMCDDA EU expert meetings
(Croatia and Turkey)
• Country overviews published in both English and
national language (recto / verso)
• Information map
• Needs Assessment Report for each country
• ESPAD survey in 4 out of 5 countries
• TDI training in Montenegro
21
What are the objectives of IPA 3?
General objective:
To further strengthen the capacity of IPA Beneficiaries to establish,
at national level, a drug information system compatible with the
EMCDDA standards
Specific objectives:
1. to provide support to the establishment or to the strengthening of
a national focal point and for its future integration in the Reitox
Network
2. to provide direct support to data collection and to the
implementation of the national reporting packages
3. to establish and to strengthen the institutional relationship with
partner countries, in liaison with the EU Institutions and
International Organisations.
22
Coaching system
• Appointment by each Beneficiary of a
National correspondent responsible for the
coordination and implementation of the
activities at national level
• Selection of a Reitox Coach from the Reitox
network of Focal Point, responsible for the
coordination or implementation of the
activities from the EU side
23
Needs assessment mission
Delegation composed by EMCDDA staff,
Reitox coach and EU experts meet with all
the main national actors involved in the drugs
area.
24
Establishment of national working groups
• Mission is to produce a country overview and
an information map
• Composed by 5-6 national experts
25
What has been achieved so far under IPA 3?
Croatia
• Co-financing of the first ever General Population
Survey;
• Translation in Croatian of the Handbook on Building
a National Drugs Observatory;
• Study visit to the Austrian focal point
• EWS national conference
• Best practice on prevention training in 4 Croatian
cities
26
What has been achieved so far under IPA 3?
Former Yugoslav Republic of Macedonia
o
o
o
o
o
Extended and updated Country Overview
Updated information map
National Report in line with EMCDDA guidelines
EMCDDA participation to a supply reduction seminar
Participation to a TDI training financed by Global
fund
27
What has been achieved so far under IPA 3?
Albania
o Extended and updated Country Overview
o Updated information map
o National Report in line with EMCDDA guidelines
Financing of the ESPAD survey
o Adaptation, at national level, of the PDU protocol and
the upgrade of the drug related treatment demand
data collection system
o Translation of technical documents (5 KI) for data
collection into Albanian
28
What has been achieved so far under IPA 3?
Bosnia Herzegovina
o
o
o
o
Extended and updated Country Overview
Updated information map
National Report in line with EMCDDA guidelines
Workshops on the Treatment Demand Indicator and
pilot data collection
o 2010 data collection of drug related deaths
29
What has been achieved so far under IPA 3?
• Kosovo (under UNSCR 1244/99)
o
o
o
o
o
o
Needs Assessment Report
1st information map
1st Country Overview
Financing of ESPAD survey
National Treatment Demand Indicator Seminar
Translation of technical documents (5 KI) for data
collection into Albanian
30
What has been achieved so far under IPA 3?
Montenegro
•
•
•
•
Extended and updated Country Overview
Updated information map
National Report in line with EMCDDA guidelines
Study visit to one or two EU national focal points to
gather examples of ‘good practice’ around focal point
building is planned
31
What has been achieved so far under IPA 3?
Serbia
•
•
•
•
Updated and extended country overview
Updated information map
National Report in line with EMCDDA guidelines
Training activities in the fields of the Treatment
Demand and the Drug Related Deaths Indicators
32